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Dynamic regulation of the mitochondrial network by mito-
fusins (MFNs) modulates energy production, cell survival, and
many intracellular signaling events, including calcium han-
dling. However, the relative importance of specific mitochon-
drial functions and their dependence on MFNs vary greatly
among cell types. Osteoclasts have many mitochondria, and
increased mitochondrial biogenesis and oxidative phosphoryla-
tion enhance bone resorption, but little is known about the
mitochondrial network or MFNs in osteoclasts. Because expres-
sion of each MFN isoform increases with osteoclastogenesis, we
conditionally deleted MFN1 and MFN2 (double conditional KO
(dcKO)) in murine osteoclast precursors, finding that this
increased bone mass in young female mice and abolished oste-
oclast precursor differentiation into mature osteoclasts in vitro.
Defective osteoclastogenesis was reversed by overexpression of
MFN2 but not MFN1; therefore, we generated mice lacking
only MFN2 in osteoclasts. MFN2-deficient female mice had
increased bone mass at 1 year and resistance to Receptor Acti-
vator of NF-B Ligand (RANKL)-induced osteolysis at 8 weeks.
To explore whether MFN-mediated tethering or mitophagy is
important for osteoclastogenesis, we overexpressed MFN2 vari-
ants defective in either function in dcKO precursors and found
that, although mitophagy was dispensable for differentiation,
tethering was required. Because the master osteoclastogenic
transcriptional regulator nuclear factor of activated T cells 1
(NFATc1) is calcium-regulated, we assessed calcium release
from the endoplasmic reticulum and store-operated calcium
entry and found that the latter was blunted in dcKO cells.
Restored osteoclast differentiation by expression of intact
MFN2 or the mitophagy-defective variant was associated with
normalization of store-operated calcium entry and NFATc1 lev-
els, indicating that MFN2 controls mitochondrion– endo-
plasmic reticulum tethering in osteoclasts.
Mitochondria exist within a highly regulated and dynamic
network in most cell types. Termed mitochondrial dynamics,
the linked processes of fission, fusion, and mitophagy play an
important role in mitochondrial homeostasis. Changes in mito-
chondrial networks are frequent, and this architecture varies
depending on the developmental or metabolic needs of a cell
(reviewed in Refs. 1, 2). Mitofusin1 (MFN1)2 and Mitofusin2
(MFN2), transmembrane GTPases on the outer mitochondrial
membrane, control mitochondrial architecture by tethering
adjacent mitochondria and initiating fusion. MFN2 addition-
ally mediates tethering of mitochondria to the ER, promotes
mitophagy, and allows mitochondrial transport down axons.
MFN1 and MFN2 are necessary for survival, as global deletion
of either protein results in embryonic lethality prior to embry-
onic day 12.5 in mice (3). Double deletion of MFN1 and MFN2
leads to even earlier mortality and, in mouse embryonic fibro-
blasts, causes severe fragmentation of mitochondrial networks
(3).
In humans, the nervous system is highly impacted by MFN2
defects, and MFN2 mutations are linked to neuropathies
(reviewed in Refs. 4, 5). The human syndrome most associated
with mutations in MFN2 is Charcot–Marie–Tooth type 2A
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(CMT2A), a neurodegenerative disorder in which motor and
sensory defects develop within the first two decades of life (6).
Mice with homologous Mfn2 mutations have sensory and/or
motor defects and axonal degeneration accompanied by altered
mitochondrial dynamics (7–9), and cultured human cells from
CMT2A patients display decreased electrical properties and
reduced mitochondrial membrane potential (10, 11). Models
lacking mitofusins also yield conditions of myocardial hyper-
trophy, heart tube contractile dysfunction, vascular smooth
muscle cell proliferation, and skeletal muscle atrophy, to name
a few (12–15). To our knowledge, effects on the skeleton have
not been reported in CMT2A mouse models or human
patients. Additionally, no human syndromes with MFN1 muta-
tions have been described.
Bone homeostasis relies on the coupled activity of osteoblast
and osteoclast (OC) cells that build and resorb the bone matrix,
respectively. OCs are rich in mitochondria, and differentiation
from bone marrow macrophage (BMM) precursors to OCs is
associated with a significant increase in mitochondrial DNA
copy number, oxidative phosphorylation subunit protein levels,
and oxygen consumption rates (16). Previous investigations of
mitochondria in the OC lineage have largely focused on the role
of mitochondrial biogenesis and oxidative phosphorylation
in supporting OC function (17–19). We were prompted to
explore the role of mitochondrial dynamics in OCs because this
specialized cell type is mitochondrion-rich and undergoes vast
morphological changes to become a mature multinucleated
cell. We hypothesized that mitochondrial fusion might accom-
pany OC precursor fusion during osteoclastogenesis and that
tethering of mitochondria to each other or the ER is important
for OC formation and/or function. To test this, we generated a
mouse model in which MFN1 and MFN2 are conditionally
deleted in the OC lineage with LysM-cre. We found that knock-
out of both homologs is associated with increased bone mass in
female animals and blunted osteoclastogenesis in culture. Res-
cue experiments in vitro revealed that MFN2 more strongly
induces osteoclastogenesis than MFN1 and that in vivo, deple-
tion of MFN2 is protective against age- and RANKL-induced
bone loss. Last, we demonstrate mitochondrial tethering to be
the predominant function of MFN2 in OCs, associated with
changes in Ca2–NFATc1 signaling.
Results
Bone mass is increased in female mice lacking MFN1 and
MFN2 in the OC lineage
Because OCs undergo vast morphological changes to
become mature multinucleated cells, we hypothesized that
alterations in mitochondrial dynamics, and fusion in particular,
accompany and modulate this event. To prevent mitochondrial
fusion, we employed mice with floxed alleles for both Mfn1 and
Mfn2, directing their excision to the OC lineage with LysM-cre.
All of our mice were mated onto a homozygous cre background
(LysMc/c) to increase recombination efficiency. We inter-
crossed double heterozygous (LysMc/c; (Mfn1/2)fl/  ctrl)
mice to generate double knockout (LysMc/c; (Mfn1/2)fl/fl;
dcKO) littermates, which were born at normal Mendelian
ratios. Subsequently, these dcKO progeny were mated to the
double-heterozygous ctrl mice to produce our experimental
groups. In parallel, double heterozygous ctrl mice were bred
to cre-only (LysMc/c;(Mfn1/2)/) mice to generate a cohort
of ctrl and cre-only littermates. Importantly, there was no
difference in bone mass parameters between ctrl and cre-
only groups (Fig. S1, A–N), indicating that ctrl double-
heterozygous animals are an appropriate control group for
dcKO mice.
dcKO mice showed no obvious gross phenotypes and had
weights identical to ctrl littermates (Fig. S2, A and B). Male and
female animals were sacrificed at 2 months of age, a time of high
OC activity, and basal bone morphology was assessed by CT
of dissected femora. We found a strong bone phenotype in
female animals at this age, with all trabecular and cortical
parameters consistent with a high bone mass (significantly
increased bone volume (BV) per total volume (TV), bone min-
eral density (BMD), trabecular number (Tb.N), and cortical
thickness (Cort.Th)) (Fig. 1, A and B, and Fig. S2, C–F). Inter-
estingly, males showed no significant differences between ctrl
and dcKO groups in any of these parameters (Fig. 1, C and D,
and Fig. S2, G–J). Serum CTX-1 levels were decreased in
dcKO females, indicating a decrease in bone catabolism (Fig.
2A). Histomorphometry showed that OC surface and num-
ber in dcKOs trended lower than in ctrls in female mice (Fig.
2, B–E). Osteoblast–OC coupling was not affected by loss of
MFN1 and MFN2 in OCs; indices of bone formation, such as
serum P1NP, mineralizing surface, mineral apposition rate,
and bone formation rate, were unchanged between groups
(Fig. 2, F–K).
Osteoclastogenesis is inhibited in MFN1/2-deficient cultures
To more closely characterize the impact of mitofusin loss in
the OC lineage, BMMs were expanded from bone marrow of
ctrl and dcKO mice. Compared with cre-only OCs with WT
mitofusin expression, double-heterozygous ctrls produced less
MFN1 and MFN2 protein, which was further diminished in
dcKO cells (Fig. 3A). dcKOs were unable to respond to RANKL
and differentiate into OCs on plastic wells, whereas differenti-
ation of ctrls was intact (Fig. 3B). When cultured on bone,
resorption was also minimal (Fig. 3C). Consistently, levels of
the OC markers NFATc1, DC-STAMP, and CTSK were
reduced in dcKOs at the mRNA level (Fig. 3, D–F). Western
blots also demonstrated lower levels of Cathepsin K (CTSK)
and C-SRC proteins, which supports a defect in OC differ-
entiation (Fig. 3G).
The levels of protein and mRNA for both MFN homologs
increased throughout osteoclastogenesis in WT cells (Fig. 4, A
and B). Therefore, we sought to determine whether MFN1 or
MFN2 was dominant in contributing to the dcKO phenotype
and attempted to rescue the defect in OC formation by retro-
virally expressing MFN1 or MFN2 in dcKO BMMs. We found
that overexpression of MFN2, but not MFN1, restored full OC
differentiation, suggesting that MFN2 is the dominant mito-
fusin homolog that supports osteoclastogenesis (Fig. 4, C–E).
MFN2 plays a role in OCs in vivo
To assess whether loss of MFN2 alone in OC lineage cells
would have an effect on bone mass in vivo, we generated litter-
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mate cohorts of mice with WT Mfn2 (LysMc/c; Mfn2/; cre-
only) and conditionally targeted Mfn2 (LysMc/c; Mfn2fl/fl; Mfn2
cKO). We confirmed depletion of MFN2 by evaluating protein
and mRNA expression (Fig. 5, A and B). Although we observed
upward trends in female Mfn2 cKOs at 2 and 4 months of age,
the differences in BV/TV and BMD did not become statistically
significant until 12 months of age; there was no difference in
bone mass between male cKO and male cre-only mice at any
age examined (Fig. 5, C–F, Table 1, and Table S1). The percent-
age of trabecular bone retained from 4 months to 12 months
was 24% for ctrls versus 46% for cKO females (64% versus 63%
for males). Tartrate resistant acid phosphatase (TRAP)-stained
2-month-old tibia sections show a trend toward lower OC
number and surface per bone surface (Oc.N/BS and Oc.S/BS) in
female cKO mice (Fig. S3). Thus, loss of MFN2 has limited
effects on basal bone mass in young animals, whereas it protects
female mice from age-related bone loss.
Our group and others have previously observed that chal-
lenging animals with a stimulus for pathological bone loss
can unmask a robust OC phenotype even when basal changes
are not prominent (20 –23). We hypothesized that this may
be the case for Mfn2 cKO animals and therefore induced
acute osteolysis in 2-month-old animals. Male and female
cre-only and cKO mice were challenged with intraperitoneal
RANKL injection, which stimulates OC activity and induces
significant loss of trabecular bone in 2 days. Although cre-
only males, male cKOs, and cre-only females lost 30%– 45%
of trabecular bone fraction following RANKL injection,
female cKOs were protected from induced osteolysis, show-
ing no significant change (Fig. 5, G–I, and Fig. S4). There-
fore, even with a strong OC stimulus, male mice are not
affected by loss of MFN2, whereas female mice require
MFN2 in the OC to respond.
Mitochondrial tethering is the dominant MFN2 mechanism
contributing to osteoclastogenesis in vitro
MFN2 has two primary molecular functions, tethering/fu-
sion and mitophagy, that can be selectively disabled via muta-
tion of threonine and serine residues to constitutively activate
or ablate the signal for mitophagy (24). MFN2 T111E-S442E
(MFN2-EE) mimics phosphorylation by PINK1 kinase, driving
spontaneous mitophagy and preventing fusion, leading to a
highly fragmented mitochondrial network. In contrast, MFN2
T111A-S442A (MFN2-AA) has the opposite effect; the non-
phosphorylatable MFN2 residues eliminate mitophagy but
allow normal tethering and fusion (Fig. 6A) (24, 25). To exam-
ine the ability of either MFN2 function to impact OCs, we ret-
rovirally overexpressed each mutant, along with empty vector
(V) and MFN2-WT controls, in female dcKO BMMs that were
defective in producing OCs (Fig. 6B). To verify that mutants
were functioning properly, we stained transduced BMMs with
MitoTracker Green and LysoTracker Red prior to live-cell con-
Figure 1. Trabecular and cortical bone mass are increased in 2-month-old female mice lacking MFN1 and MFN2 in the OC lineage. A and B, BV/TV (A) and
Cort.Th (B) are significantly elevated in female dcKOs compared with ctrls in the distal femur at 2 months of age, as shown by CT. Representative recon-
structions of analyzed regions above the growth plate and at mid-shaft are shown in the right panels. Scale bars  200 m. C and D, 2-month-old males were
evaluated for BV/TV (C) and Cort.Th (D). **, p  0.01; ns, not significant; unpaired t test with Welch’s correction.
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focal microscopy (Fig. 6C). Mitochondrial colocalization with
lysosomes, an indication of mitophagy, was minimal under all
conditions. Similar to previous studies with these constructs,
MFN2-WT and MFN2-AA increased tethering and fusion, as
manifested by increased mitochondrial aspect ratios (mito-
chondrial length/mitochondrial width) compared with less
fused V and MFN2-EE samples (Fig. 6D). Following 6 days of
RANKL exposure, cultures were fixed and stained for TRAP
(Fig. 6, E and F). We found that transduction of dcKO BMMs
with MFN2-AA restored osteoclastogenesis to a level compa-
rable with MFN2-WT, indicating that the mitophagy function
of MFN2 is dispensable for osteoclastogenesis. In contrast,
transduction with MFN2-EE had only a minimal effect on oste-
oclastogenesis, suggesting that tethering/fusion by MFN2 is
necessary for osteoclastogenesis to occur efficiently (Fig. 6,
C–F). Because MNF1 was absent from these cells, this reveals
that mitochondrial tethering by MFN2 contributes to OC for-
mation in a way that MFN1 cannot.
Figure 2. Female Mfn1/2 dcKOs have decreased OC activity but no change in bone formation. A, serum CTX-1 assay shows decreased bone resorption in
2-month-old dcKO females. B and C, histomorphometry of TRAP stained tibiae reveals a modest decreases in dcKO Oc.N/BS (B) and Oc.S/BS (C). D and E,
representative TRAP-stained ctrl and dcKO femora, respectively. F–I, no differences in bone accrual between groups were observed by serum P1NP (F) or
dynamic histomorphometric analysis of trabecular bone for mineralizing surface (MS)/BS (G), mineral apposition rate (MAR) (H), and bone formation rate
(BFR)/BS (I) in tibiae. J and K, representative fluorescence images of ctrl and dcKO femora, respectively. Scale bars  400 m (low power) and 40 m (insets). *,
p  0.05; ns, not significant; one-tailed unpaired t test with Welch’s correction.
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Ca2 signaling is perturbed in pre-OCs with impaired MFN2-
mediated tethering
To further explore the mechanism through which MFN2
controls osteoclastogenesis, we assayed cytoplasmic Ca2 lev-
els with Fura-2 basally, following ATP stimulation (to release
ER calcium stores) and after addition of extracellular calcium (2
mM) to activate store-operated calcium entry (SOCE). In pre-
OCs generated with 48 h of RANKL exposure, dcKOs had
higher basal Ca2 levels and a similar ATP-mediated spike
from baseline but a muted intake of Ca2 following SOCE
activation compared with ctrls, as assessed by area under
curve quantification (Fig. 7, A–C). We used the same assay
in dcKO BMMs overexpressing MFN2-WT, -EE, and
-AA. Compared with the vector control, MFN2-WT and
MFN2-AA increased responsiveness to extracellular Ca2
whereas MFN2-EE did not, suggesting that the tethering
function of MFN2 regulates SOCE (Fig. 7, D–F). Congruent
with restoration of osteoclastogenesis, cells with improved
SOCE (MFN2-WT and -AA) had increased NFATc1 levels
compared with dcKOs with V or MFN2-EE transduction,
Figure 3. Osteoclastogenesis is defective in BMMs derived from dcKO bone marrow. A, MFN1 and MFN2 protein levels are progressively decreased in
RANKL-treated ctrls and dcKOs compared with RANKL-treated cre-only BMMs. B, BMMs cultured with RANKL for 5 days form OCs in ctrls but not in dcKOs. Scale
bars  400 m. C, bone resorption is congruently inhibited; resorption pits are outlined in dotted white. Scale bars  200 m. D–G, mRNA levels of the OC
markers NFATc1 (D), DC-STAMP (E), and CTSK (F) are diminished in dcKOs after 3 and 5 days of differentiation in RANKL, correlating with C-SRC and CTSK protein
levels during osteoclastogenesis (G). *, p  0.05; ***, p  0.001; ****, p  0.0001; ns, not significant; unpaired t test with Welch’s correction. n  3 biological
replicates.
Figure 4. Although both homologs increase during OC formation, addition of MFN2 drives osteoclastogenesis in vitro more efficiently. A and B, protein
(A) and mRNA (B) expression through 6 days of osteoclastogenesis in WT BMMs shows parallel increases in MFN1 and MFN2 expression. C, dcKO BMMs were
transduced with retroviral pMX-Vector, V, pMX-MFN1, MFN1, or pMX-MFN2, and mitofusin proteins were detected via Western blotting. D and E, following
RANKL treatment for 6 days, cultures were stained with TRAP, and OCs were enumerated, revealing robust osteoclastogenesis in MFN2-treated but not
MFN1-treated cells. The graphs represent three biological replicates. Scale bars  400 m. *, p  0.05; **, p  0.01; ****, p  0.0001; ns, not significant; one-way
ANOVA.
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linking the MFN2 tethering function to the Ca2–NFATc1
axis during OC differentiation (Fig. 7G).
Discussion
An abundance of mitochondria has been deemed important
for function of the OC, and increases in mitochondrial proteins
are associated with differentiation from myeloid precursors
(16, 26, 27). Mitochondrial biogenesis, mediated by PGC1 and
PGC1, plays an important role, as global deletion of either of
these factors leads to increased trabecular bone mass (17, 28).
Further, conditional PGC1 deletion in OCs results in im-
paired cytoskeletal organization and bone resorption (19). OCs
have been reported to utilize oxidative phosphorylation and
aerobic glycolysis, and it has been suggested that the primary
function of mitochondria may not be ATP generation at the
ruffled border (29).
To better understand the role of mitochondria and put
into context the elongated organelles observed in human
OCs (27), we aimed to perturb mitochondrial network orga-
nization. We found that dual depletion of the key mitochon-
drial dynamics proteins MFN1 and MFN2 in the OC lineage
leads to increased bone mass in female mice in vivo, accom-
Figure 5. Female mice lacking MFN2 alone in the OC lineage are protected from bone loss with age and RANKL-induced osteolysis. A and B, MFN2
expression is decreased in Mfn2 cKO OCs in vitro compared with cre-only at the protein (A) and RNA (B) levels. C–F, femora from cre-only and Mfn2 cKO mice at
12 months of age were analyzed by CT for BV/TV in females (C), BV/TV in males (D), BMD in females (E), and BMD in males (F). Trabecular bone mass is increased
in female cKOs but not males. G–I, acute bone loss was induced by intraperitoneal RANKL injection at 2 months of age in cre-only and Mfn2 cKO mice, and
assessed by CT at the distal femur. BV/TV is not decreased with RANKL treatment in female Mfn2 cKO mice (G). BV/TV decreases to a similar degree in male
Mfn2 cKO mice compared with cre-only controls (H). I, representative post-RANKL CT reconstructions from G and H. Scale bars  200 m. The untreated
cohorts are the same as those listed at 2 months of age in Table 1 and Table S1. *, p  0.05; **, p  0.01; ns, not significant; unpaired t test with Welch’s correction
in B–F and ordinary two-way ANOVA with multiple comparisons in G and H.
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panied by a decrease in serum CTX-1 levels. This corre-
sponds to an inability of OCs derived from these dcKO ani-
mals to form in culture. Previous work in the field has
focused primarily on how changes in mitochondrial content
and oxidative phosphorylation impact OC resorption (16,
19, 30, 31). Our model expands the relationship between
mitochondria and OCs by linking disruption of mitochon-
drial dynamics to inhibition of OC formation.
To determine whether MFN1 and MFN2 contribute dif-
ferentially to OC formation, we overexpressed each homolog
in dcKO BMMs in culture and found that osteoclastogenesis
was much more efficient with MFN2 than MFN1 addition.
Further, loss of MFN2 alone led to increased bone mass in
vivo, albeit delayed compared with the doubly deficient
cohort. Similarly, work with heart and skeletal muscle has
revealed that loss of MFN1 and MFN2 produces more severe
phenotypes than single knockout of either mitofusin (14, 32).
It is likely that the mitochondrial fusion function of MFN2
plays some role in OCs, which allows compensation by
MFN1 to reduce the severity of bone accrual in MFN2 singly
deficient mice, although at least one MFN2-unique role is
also important.
MFN2, but not MFN1, functions in mitophagy, mitochon-
drial transport in axons, and ER–mitochondrion interactions.
Phenotypic effects of specific mutations reveal significant cell
type specificity in these various roles. For example, fibro-
blasts derived from CMT2A patients show differences in
ER–mitochondrion spacing that correlate with disease severity,
suggesting that alteration of ER–mitochondrion tethering
contributes to pathogenicity in humans (33). In contrast,
mitophagy is required for metabolic reprogramming of mam-
malian hearts during perinatal development, but tethering by
MFN2 is dispensable for this process (24). We utilized point
mutants separating tethering and mitophagy functions to
probe which MFN2 function is important in the OC lineage and
found that the tethering function of MFN2 is necessary for
osteoclastogenesis.
The master OC transcription factor NFATc1 depends on
cytoplasmic Ca2 flux and requires dephosphorylation by cal-
cineurin for translocation to the nucleus (34), leading to ampli-
fication because of binding at its own promoter. We find that
NFATc1 mRNA levels are diminished in our dcKO cells, sug-
gesting alterations in Ca2 handling. The ER–mitochondrion
juxtaposition, regulated by the tethering function of MFN2 but
not MFN1, is known to impact Ca2 signaling (9, 33, 35). We
therefore examined cytoplasmic Ca2 levels and found that
dcKOs had a significantly reduced magnitude of SOCE. Similar
blunting of SOCE was found in C2C12 myoblasts with MFN2
knockdown (36). Interestingly, our dcKOs showed higher basal
cytoplasmic Ca2, whereas MFN2-depleted C2C12 cells and
BMMs had lower basal cytoplasmic Ca2 than controls (36, 37).
It is possible that the presence of MFN1 in the experiments with
MFN2 knockdown plays a role in basal levels, whereas MFN2 is
more important for SOCE regulation. On our MFN1/MFN2-
deficient background, we further found that the tethering-com-
petent/mitophagy-deficient MFN2-AA, but not the tethering-
deficient/mitophagy-activated MFN2-EE, restored SOCE
along with NFATc1 induction and osteoclastogenesis. Previ-
ously, we found that cells lacking TMEM178, which show
increased NFATc1 and osteoclastogenesis, have elevations in
basal cytoplasmic Ca2 and SOCE (38, 39). Thus, it is likely that
the magnitude of Ca2 excursions, rather than the basal level, is
more important for osteoclastogenesis. Mechanistically, we
propose that MFN2-mediated restoration of ER-mitochon-
drion contacts, which regulate mitochondrial Ca2 uptake, are
responsible for the ability of cells to generate the large swings in
cytoplasmic Ca2 (i.e. high-amplitude oscillations) that drive
NFATc1 activation.
We find striking sexual differences in our bone phenotypes,
and to our knowledge, this is the second report of differential
male versus female responses to mitofusin loss. Conditional
ablation of MFN2 in brown adipose tissue leads to sex-specific
remodeling of mitochondrial function; females displayed
increased ATP-synthesizing fatty acid oxidation, whereas
males experienced increased glycolytic capacity (40, 41). Al-
though loss of MFN2 in brown adipose tissue caused distinct
abnormalities in males and females, we only saw changes in
females with loss of mitofusins in the OC lineage. We previ-
ously found higher OC numbers in the trabecular compartment
of female mice, possibly explaining the greater impact on bone
mass with more abundant OCs in this sex (42). One explanation
could be that there is a threshold effect for mitofusins on OC
formation and that females are more sensitive to mitofusin
depletion than males. Further, the high bone mass phenotype
may be more severe in female dcKOs compared with single
Mfn2 cKOs because residual MFN1 expression partially com-
pensates for loss of MFN2. Consistent with this threshold
hypothesis, we see no differences in bone mass between cre-
only and double heterozygous ctrl animals despite protein lev-
els differing by about half. Because residual mitofusin proteins
were detected in our lysM-cre models, greater effects, including
increased bone mass in male mice, might be achieved with
more complete recombination in the OC lineage. Future inves-
tigations can utilize RANK-cre to target a similar early devel-
Table 1
Trabecular bone parameters are increased in female Mfn2 cKOs at 12
months of age
Femora from female cre-only and Mfn2 cKO mice were analyzed by CT at 2, 4, and
12 months (mo.) of age, revealing high bone mass in Mfn2 cKOs at 1 year. *, p  0.05;




Mfn2 cKO p value
BV/TV 2 mo. 0.085  0.021 0.102  0.026 0.145
4 mo. 0.096  0.014 0.111  0.032 0.175
12 mo. 0.023  0.014 0.051  0.037 0.012*
BMD (mg/cm3) 2 mo. 180.9  18.3 195.4  20.6 0.115
4 mo. 193.5  12.4 205.3  23.5 0.166
12 mo. 116.9  12.2 145  34.5 0.007**
Tb.N. (no./mm) 2 mo. 4.20  0.34 4.53  0.45 0.099
4 mo. 3.53  0.22 3.81  0.30 0.027*
12 mo. 1.78  0.53 2.15  0.39 0.103
Tb.Th. (mm) 2 mo. 0.040  0.003 0.041  0.003 0.295
4 mo. 0.044  0.002 0.046  0.004 0.288
12 mo. 0.051  0.006 0.050  0.006 0.495
Tb.Sp. (mm) 2 mo. 0.239  0.024 0.220  0.023 0.082
4 mo. 0.284  0.018 0.262  0.023 0.022*
12 mo. 0.605  0.150 0.481  0.083 0.057
Cort.Th. (mm) 2 mo. 0.145  0.014 0.159  0.011 0.023*
4 mo. 0.204  0.017 0.207  0.014 0.752
12 mo. 0.201  0.028 0.226  0.007 0.055
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opmental stage or Cathepsin K– cre to deplete mitofusins in
mature OCs.
In sum, our studies highlight the importance of mitofusin-
mediated organelle tethering in OC lineage cells and suggest
that mitochondrial dynamics are important in control of
bone resorption, at least in females. Preclinical experiments
have suggested that down-regulation of MFN2 may have
beneficial effects in cardiac ischemia (43, 44), and our work




Double floxed Mfn1fl/fl; Mfn1/2fl/fl animals (45), which delete
exon 4 of MFN1 and exon 6 of MFN2 upon cre recombination,
were mated to C57Bl/6 mice harboring the LysozymeM-cre
recombinase (LysM-cre) allele (46) to place all animals on a
homozygous LysM-cre background. To generate dcKOs, dou-
ble heterozygous (Mfn1fl/; Mfn2fl/;LysMc/c) mice were first
bred together, and dcKO (Mfn1fl/fl; Mfn1/2fl/fl; LysMc/c) female
progeny were mated to double-heterozygous males to generate
the cohort of double heterozygous controls and dcKOs. In par-
allel, cre-only (Mfn1/; Mfn2/; LysMc/c) females from the
original double-heterozygous matings were bred to double-
heterozygous males to generate the cohort of cre-only and con-
trol animals. The single Mfn2 cohort was generated using
heterozygous breeding pairs so that progeny genotypes in-
cluded cre-only (Mfn2/; LysMc/c) and cKOs (Mfn1/2fl/fl;
LysMc/c).
Mice were housed communally with ad libitum access to
fresh chow and water in a pathogen-free, temperature-con-
trolled barrier facility. Daily observation and weekly cage
changes were provided by staff of the Division of Comparative
Medicine. Laboratory members coordinated animal husbandry
and breeding, and the Division of Comparative Medicine vet-
erinarian assessed all health concerns. All protocols were
approved by Washington University School of Medicine’s Ani-
mal Studies Committee (protocol 20170025).
Figure 6. Restoration of MFN2 tethering function rescues osteoclastogenesis in dcKO BMMs. A, MFN2 functions in each rescue condition. B, dcKO BMMs
were transduced with retroviral pMX-Vector (V), pMX-MFN2-WT (WT), pMX-MFN2-EE (EE), and pMX-MFN2-AA (AA), and MFN2 protein was detected via Western
blotting in BMMs. C, cultures of transduced BMMs were stained with MitoTracker Green and LysoTracker Red. Scale bars  10 m (whole cells) and 2.5 m
(insets). D, quantification of mitochondrial aspect ratio (mitochondrial length/width). E, BMMs were TRAP-stained following 6 days of RANKL exposure,
revealing robust osteoclastogenesis with MFN2-AA but not MFN2-EE. Scale bars  400 m. F, quantification of OC numbers in three biological replicates. ****,
p  0.0001, ordinary one-way ANOVA.
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Following dissection of right femora from 2-, 4-, and
12-month-old animals, bones were fixed in 10% neutral buff-
ered formalin (Di Ruscio & Associates, Inc., Fenton, MO) for
24 h and then stored in 70% ethanol. Trabecular and cortical
scans were acquired proximal to the distal growth plate and at
the mid-shaft of femora, respectively (CT40, Scanco, Brütti-
sellen, Switzerland; 10-m resolution, 55 kilovoltage peak, 145
A, 300-s integration time). Thresholds were determined in a
blinded manner and analyzed with reference to accepted guide-
lines (47, 48).
CTX1 and P1NP
Serum was collected from animals fasted overnight via
mandibular bleed (BD Microtainer) and stored at 80 °C.
RatLaps CTX-1 and P1NP EIA assays were conducted
according to manufacturer’s instructions (Immunodiagnos-
tic Systems, Gaithersburg, MD; AC-06F1 and AC-33F1,
respectively).
Histomorphometry
2-month-old mice were injected i.p. with 10 mg/kg calcein
(C0875, Sigma) and 30 mg/kg Alizarin Red (A3882, Sigma) 7
and 2 days prior to sacrifice, respectively. Intact femora/
tibiae were fixed in 10% neutral buffered formalin for 24 h
prior to storage in 70% ethanol. Tissues were embedded in
methylmethacrylate and sectioned sagittally by the Wash-
ington University Musculoskeletal Histology and Morphom-
etry Core. Unstained and TRAP-stained (Sigma) slides were
imaged at 20 high resolution using a NanoZoomer 2.0 with
bright field and FITC/TRITC (Hamamatsu Photonics).
Images were then analyzed via Bioquant Osteo software
according to the manufacturer’s instructions and published
standards (v18.2.6, Bioquant Image Analysis Corp., Nash-
ville, TN) (49).
BMM isolation and osteoclast differentiation
BMMs were harvested by collecting bone marrow from dis-
sected long bones of 2-month-old female animals via centrifu-
gation at 10,000 rpm, passed through a 40-m filter, and
cultured with -MEM (Sigma, M0894) containing 10% FBS
(Gibco), 100 IU/ml penicillin/streptomycin, and 1:10 dilu-
tion of CMG 14-12 cell supernatant containing an equivalent
of 100 ng/ml Macrophage-Colony Stimulating Factor (M-CSF)
(20, 50).
Expanded BMMs were plated at a density of 9,000 and
300,000 cells/well for 96- and 6-well plates, respectively. Puri-
fied GST-RANKL at 30 ng/ml was added to -MEM containing
10% FBS, 100 IU/ml penicillin/streptomycin, and a 1:50 dilu-
tion of CMG 14-12 cell supernatant. The medium was changed
every alternate day until control wells were filled with multinu-
cleated OCs. TRAP stains were employed following 10-min fix-
Figure 7. Blunted Ca2 entry in dcKO preOCs is restored with MFN2-AA overexpression. A–C, Fura-2 staining shows elevated basal intracellular Ca2 but
blunted store-operated calcium entry after addition of extracellular Ca2 in dcKO pre-OCs. Shown is area under the curve quantification following Ca2 (B) and
ATP (C). D and E, overexpression of MFN2-WT or MFN2-AA restores Ca2 entry in dcKO pre-OCs whereas MFN2-EE does not. F, quantification of the area under
the curve. G, corresponding NFATc1 levels, evaluated by quantitative real-time PCR in mutant OCs, correlate with SOCE responsiveness. *, p  0.05; ***, p 
0.001; ****, p  0.0001; unpaired t test (B and C) or ordinary one-way ANOVA (F and G).
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ation with 4% paraformaldehyde (Polysciences, Warrington,
PA) and 0.1% Triton X-100 in PBS according to the manufactu-
rer’s instructions (Sigma, 387A).
Resorption assay
Expanded BMMs were seeded on bovine bone slices and dif-
ferentiated to OCs with purified GST-RANKL as above. At
maturity, bone slices were fixed for 10 min with 4% paraformal-
dehyde and 0.1% Triton X-100 in PBS. Bone slices were incu-
bated in 0.5 NaOH for 30 s and kept hydrated in PBS. Cells were
scraped off bone slices with a cotton swab, and bone slices were
incubated with 20 g/ml peroxidase-conjugated wheat germ
agglutinin in PBS (Sigma, 61767) for 30 min. Subsequently,
slices were washed three times in PBS and incubated with a
DAB Chromogen Kit (Biocare Medical, BDB2004H) at 37 °C
for 30 min. Slices were left to air-dry and imaged under a bright
field at 20.
Quantitative real-time PCR
Following collection of cells with TRIzol (Life Technologies),
solutions were centrifuged at 12,000  g, and the aqueous layer
was extracted with phenol:chloroform. An equal volume of 70%
ethanol was added, and the remaining RNA isolation was done
using the NucleoSpin RNA II Kit (Clontech Laboratories, Palo
Alto, CA; 740955.50). 1 g of RNA was placed into the cDNA
Ecodry Premix Kit prior to the quantitative PCR program being
run on ABI QuantStudio 3 with iTaq Universal SYBR Green
Supermix (Bio-Rad, 1725121). Each reaction proceeded at
50 °C for 2 min, 95 °C for 10 min, and then 40 cycles of 95 °C for
15 s and 60 °C for 1 min. Relative expression was calculated as
100  2 (target CT  B2M CT). Primer sequences were as follows:
MFN1, TTGGCAGGACAAGTAGTGGC (forward) and AGC-
AGTTGGTTGTGTGACCA (reverse); MFN2, AAGCACTT-
TGTCACTGCCAAG (forward) and TTGTCCCAGAGCAT-
GGCATTG (reverse); NFATc1, GGTAACTCTGTCTTTCT-
AACCTTAAGCTC (forward) and GTGATGACCCCAGCA-
TGCACCAGTCACA (reverse); DC-STAMP, ACAAACAGT-
TCCAAAGCTTGC (forward) and TCCTTGGGTTCCTTG-
CTTC (reverse); CTSK, AGGCAGCTAAATGCAGAGGG-
TACA (forward) and AGCTTGCATCGATGGACACAGAGA
(reverse); B2M, CTGCTACGTAACACAGTTCCACCC (for-
ward) and CATGATGCTTGATCACATGTCTCG (reverse).
Western blotting
Radioimmune precipitation assay buffer (20 mM Tris (pH
7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100,
2.5 mM sodium pyrophosphate, 1 mM -glycerophosphate, 1
mM Na3VO4, and 1 mM NaF) with 1:50 HALT protease and
phosphatase inhibitor (Thermo Fisher Scientific, Waltham,
MA; 1861280) was used to lyse BMM and OC cells following
two washes in PBS. Lysates were vortexed and centrifuged at
700  g. Supernatant was quantified with a BCA assay (Bio-
Rad), and 20 g was loaded to a 10% SDS-PAGE gel. Gels were
run at 80 V for 2 h and transferred to nitrocellulose by wet
transfer at 100 V for 90 min. Blocking was done in TBS and 0.1%
Tween 20 with 5% milk. Membranes were probed with primary
antibodies overnight at 4 °C (sc-50330, 1:500, Mfn1, Santa Cruz
Biotechnology, Dallas, TX; ab56889, 1:1000, Mfn2, Abcam,
Cambridge, UK; MAB3324, 1:1000, CTSK, EMD Millipore,
Burlington, MA; and c-Src, 1:1000, a mAB developed by S. Teit-
elbaum, St. Louis, MO). Actin was used as a loading control at
1:10,000 (A228, Sigma-Aldrich, St. Louis, MO). Imaging was
done using SuperSignal West Femto substrate (Thermo Fisher
Scientific, 34095) and a chemiluminescence imager (Syngene,
Cambridge, UK).
Retroviral overexpression
MFN1-Myc and MFN2-Myc were obtained from Addgene
(plasmids 23212 and 23213, respectively). MFN2-WT, MFN2-
EE, and MFN2-AA were generated by Gerald Dorn (24). Each
gene was cloned into the pMX retroviral vector and transfected
into Platinum-E (platE) cells by calcium phosphate precipita-
tion (51, 52). Each insert was also sequenced to verify the pres-
ence or absence of the desired point mutations. PlatE superna-
tant was harvested 48 and 72 h post-transfection, filtered
through 0.45 m, and added to BMMs with -MEM, 10% FBS,
and 100 IU/ml penicillin/streptomycin, 1:10 CMG, and 8 g/ml
Polybrene (Sigma, H9268) on 2 consecutive days. 24 h following
final virus addition, 1 g/ml blasticidin (Sigma, 203350) was
added to select infected BMMs.
Induced osteolysis
2 month old ctrl and Mfn2 cKO animals were injected i.p.
with 1 mg/kg of body weight GST-RANKL twice, 24 h apart, as
published previously (53). 50 h after the first injection, animals
were sacrificed, and femoral trabecular bone was evaluated by
CT.
Confocal imaging
Cultured BMMs transduced with vector, MFN2-WT,
MFN2-EE, and MFN2-AA retroviruses were plated on 25-mm
glass round coverslips at 500,000 cells/well, washed with phenol
red-free DMEM (Thermo Fisher), and stained with 200 nM
MitoTracker Green FM and 200 nM LysoTracker Red (M7514
and L7528, Molecular Probes, Eugene, OR) for 30 min at 37 °C.
Following incubation, cells were washed again and kept in
DMEM with 10% FBS, 10% CMG, and 10 g/ml Hoechst
(Thermo Fisher). Confocal imaging was performed on a Nikon
Ti confocal microscope using a 60 1.3 numerical aperture oil
immersion objective with the coverglass loaded onto a chamber
(Warner Instruments, RC-40LP, Hamden, CT) in modified
Krebs–Henseleit buffer (138 mM NaCl, 3.7 mM KCl, 1.2 mM
KH2PO4, 15 mM glucose, 20 mM HEPES, and 1 mM CaCl2).
Cytoplasmic Ca2 measurement
BMMs were plated in 29-mm glass-bottom plates at 300,000
cells/plate (Cellvis, D29-14-1.5-N, Mountain View, CA) and
exposed to 30 ng/ml RANKL for 48 h. Cells were washed and
incubated at 37° for 30 min in Hanks’ balanced salt solu-
tion (HBSS) containing 2 mM CaCl2, 1 mM MgCl2, 10 ng/ml
humanM-CSF (Biolegend), 30 ng/ml RANKL, and 2 M Fura-2.
Cells were washed and kept in Hanks’ balanced salt solution
with 1 mM MgCl2 without Ca2, 10 ng/ml humanM-CSF, and
30 ng/ml RANKL for imaging. 35– 85 cells/plate were mea-
sured at wavelengths of 340 and 380 every 2 s on an Olympus
IX-71 inverted microscope with a Lamda-LS illuminator at the
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Washington University Hope Center and the Center for Inves-
tigation of Membrane Excitability Diseases Live Cell Imaging
Facility. 100 M ATP and 2 mM CaCl2 were used as stimuli as
indicated.
Statistics
Two-way ANOVA with Tukey’s multiple comparisons and
one- or two-tailed unpaired t tests with Welch’s correction
were performed with GraphPad Prism built-in statistical anal-
ysis (GraphPad Software, Inc., La Jolla, CA). All data are repre-
sented as mean  S.D. with three or more biological replicates.
p values are designated as follows: *, p  0.05; **, p  0.01; ***,
p  0.001; ****, p  0.0001.
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